REG - Futura Medical PLC - AIM Disclosure <Origin Href="QuoteRef">FUM.L</Origin>

Futura MedicalAnnouncement

16/03/2015 17:50

RNS Number : 5898H
Futura Medical PLC
16 March 2015
 For immediate release 
16 March 2015
Futura Medical plc
("Futura" or the "Company")
AIM Disclosure
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, has today been informed of the following disclosure in accordance with the requirements of Rule 17 (disclosure of miscellaneous information). On 16 March 2015, administrators were appointed to Hume Capital Securities plc, a company of which Jonathan Freeman, a Non-Executive Director of Futura, was a non-executive director since March 2012.
For any further information please contact:
Futura Medical plc

James Barder, Chief Executive
Tel: +44 (0)1483 685 670
mail to: james.barder@futuramedical.com
www.futuramedical.com


N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell - Corporate Finance
Brough Ransom - Sales
Tel:+44 (0) 20 7496 3000
For media enquiries please contact: 

Buchanan

Mark Court / Sophie Cowles / Stephanie Watson
Tel: +44 (0)20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCPKADQOBKDDND